Evidence map›Paper›PMID 39370483›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.

Yutaka Negoro, Taichi Maeda, Hiroyuki Igarashi, Mina Shigemori, Toshihiro Tanaka, Yukio Ito, Norihiko Tanizawa, Shota Nishikawa, Jyunya Ogawa, Yukio Kamitani and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yutaka NegoroDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan. ynegoro@u-fukui.ac.jp.ORCID http://orcid.org/0000-0003-0440-8380
Taichi MaedaDepartment of Pharmacy, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Hiroyuki IgarashiDepartment of Pharmacy, Fukui-Ken Saiseikai Hospital, Fukui, Japan.
Mina ShigemoriDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.
Toshihiro TanakaDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.
Yukio ItoDepartment of Pharmacy, Fukui-Ken Saiseikai Hospital, Fukui, Japan.
Norihiko TanizawaDepartment of Pharmacy, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Shota NishikawaDepartment of Pharmacy, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Jyunya OgawaDepartment of Pharmacy, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Yukio KamitaniDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.
Kyohei WatanabeMedical Research Support Center, University of Fukui Hospital, Yoshida-Gun, Fukui, Japan.
Hitoshi TsukamotoDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.
Nobuyuki GotoDepartment of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRamucirumab (RAM) is recommended as premedication with H

methodsThis was a noninferiority, multicenter, retrospective trial conducted in three Japanese centers to assess the incidence of IRRs in patients receiving RAM plus nab-PTX for gastric cancer between 2018 and 2023. Patients with gastric cancer receiving RAM plus nab-PTX were divided into groups with and without H

resultsNinety patients were evaluated, with non-H

conclusionRAM plus nab-PTX for gastric cancer with DEX premedication may be possible without H

Indexed as

AlbuminsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasonePaclitaxelPremedicationRamucirumabStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle Aged130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedDexamethasonePaclitaxelRamucirumabAntihistamines premedicationGastric cancerInfusion-related reactionsNab-PaclitaxelRamucirumab

Identifiers

PMID39370483
PMCPMC11456548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.